Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Mao H. LIN, Wo L. YUAN, Tu C. HUANG, Hai F. ZHANG, Jing T. MAI, Jing F. WANG
Department of Cardiology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, P.R. China
INTRODUCTION: Telemedicine interventions had been found to effectively reduce all-cause mortality and hospital admission rate of the patients with heart failure (HF). This study aims to update the clinical benefit of telemedicine for HF.
EVIDENCE ACQUISITION: Literature databases (updated to June 30, 2016) were searched for randomized controlled trials for HF patients, in which the participants were randomized into telemedicine group (tele-transmission, telephone-supported care, and implantable monitoring) or the usual standard care group.
EVIDENCE SYNTHESIS: A total of 42 studies were included. For the telemedicine groups in general, all-cause mortality (P = 0.001), HF-related admission rate (P <0.001), HF-related length of stay (P = 0.041) were significantly lower compared with the control group. For the tele-transmission group, all-cause mortality (P=0.001), HF-related admission rate (P=0.008), HF-related length of stay (P = 0.039) and HF-related mortality (P=0.001) were significantly lower compared with the control group. For the telephone-supported care group, only HF- related admission rate (P<0.001) was significantly lower compared with the control group. Implantable monitoring group showed no significant difference in all-cause mortality compared with the control group.
CONCLUSIONS: Overall, telemedicine was shown to be beneficial in patients with heart failure. Home-based tele-transmission interventions effectively reduce all-cause mortality and HF- related hospital admission, length of stay and mortality. Telephone-supported care only show benefit in reduction of HF-related hospital admission rate.